In our analysis none of them significantly altered the ovarian cancer risk in the groups under study, except for the BRCA1+ group where, for heterozygotes for p.Val660Leu polymorphism, a significant increase of cancer risk was found. This evidence concerns the gene BRCA1 and ovarian cancer.